Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use.
docosahexaenoic acid
fibrosis
inflammation
nonalcoholic steatohepatitis
steatosis
Journal
Annual review of nutrition
ISSN: 1545-4312
Titre abrégé: Annu Rev Nutr
Pays: United States
ID NLM: 8209988
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
medline:
22
8
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic fatty liver disease worldwide, particularly in obese and type 2 diabetic individuals. Currently, there are no therapies for NAFLD that have been approved by the US Food and Drug Administration. Herein, we examine the rationale for using ω3 polyunsaturated fatty acids (PUFAs) in NAFLD therapy. This focus is based on the finding that NAFLD severity is associated with a reduction of hepatic C
Identifiants
pubmed: 37207355
doi: 10.1146/annurev-nutr-061021-030223
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM